<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9262">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05701774</url>
  </required_header>
  <id_info>
    <org_study_id>C614</org_study_id>
    <nct_id>NCT05701774</nct_id>
  </id_info>
  <brief_title>Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome</brief_title>
  <official_title>An Open-Label Study of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Prader-Willi Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soleno Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soleno Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline)&#xD;
      extended-release tablets) in patients with Prader-Willi syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2023</start_date>
  <completion_date type="Anticipated">June 2028</completion_date>
  <primary_completion_date type="Anticipated">June 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of DCCR (adverse events. Safety analyses will be conducted in all subjects who receive at least one dose of DCCR in the C614 study. ( Adverse events)</measure>
    <time_frame>Baseline to Week 262 or until resolution of certain adverse events</time_frame>
    <description>Assess the safety of DCCR by evaluating the incidence and severity of adverse events.&#xD;
Safety analyses will be conducted in all subjects who receive at least one dose of DCCR in the C614 study. Adverse events will be described by type and level of severity.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>DCCR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 - 525 mg DCCR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCCR</intervention_name>
    <description>Once daily oral administration</description>
    <arm_group_label>DCCR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide voluntary, written informed consent (parent(s) / legal guardian(s) of&#xD;
             patient); provide voluntary, written assent (subjects, as appropriate)&#xD;
&#xD;
          2. Participant must:&#xD;
&#xD;
               1. Have participated in and completed the Study C602 Randomized Withdrawal (RW)&#xD;
                  Period;&#xD;
&#xD;
               2. Have participated in but discontinued from the Study C602 RW Period and at least&#xD;
                  16 weeks have elapsed since the date of their randomization into the C602 RW&#xD;
                  Period; or&#xD;
&#xD;
               3. Have participated in Study C602 OLE period, did not consent to participate in the&#xD;
                  RW Period, and at least 16 weeks have elapsed since the date of their C602&#xD;
                  Open-Label Extension End of Treatment Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive urine pregnancy test (in females of child-bearing potential)&#xD;
&#xD;
          2. Females who are pregnant or breastfeeding, and/or plan to become pregnant or to&#xD;
             breast-feed during or within 30 days after study participation.&#xD;
&#xD;
          3. Participation in a clinical study of an investigational drug (including approved drugs&#xD;
             for unapproved uses), investigational device, or therapeutic intervention subsequent&#xD;
             to the C602 Open-Label Extension End of Treatment Visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>C614 Project Manager</last_name>
    <phone>650 353 2051</phone>
    <email>C614ProjectManager@soleno.life</email>
  </overall_contact>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 18, 2023</study_first_submitted>
  <study_first_submitted_qc>January 26, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>January 26, 2023</last_update_submitted>
  <last_update_submitted_qc>January 26, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

